Companies to develop new tumour marker:
This article was originally published in Clinica
Canada's York Medical and its partner Centre for Molecular Immunology (CIM) are to develop a monoclonal antibody for diagnosing cancers of epithelial origin, such as those in the head, neck, breast and lung. The product, DiaCIM, will use the human version of the monoclonal antibody hR3 to identify cancers that over-express epidermal growth factor receptor (EGF-r), which is associated with the continuing growth of cancer cells, metastatic spread and poor prognosis. DiaCIM could also help identify patients who may respond to therapeutic versions of hR3, said Mississauga, Ontario-based York Medical.
You may also be interested in...
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.
In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into the impact on biopharma commercial activities.